Capital Reduction to Cover Deficits, No Specific Ratio Disclosed


  • Purpose and method: Capital reduction via share consolidation to cover deficits; fractional shares to be paid in cash.
  • Legal procedure: Resolved by ordinary resolution at shareholders' meeting; creditor objection procedure omitted (Commercial Act Articles 438(2) and 439(2)).
  • Undisclosed items: Key figures such as reduction ratio, pre/post shares outstanding, and capital change are not disclosed, requiring caution in investment decisions.

KOSDAQ Filing Information


  • Current Report (Capital Reduction Decision)
  • Company: NGeneBio (354200)
  • Submission: NGeneBio Co., Ltd.

  • Shares: 26,809,750
  • Price: 1,687 KRW
  • Market Cap: 45.2 B KRW